Sperm Protein 17 in Human Nervous System Tumors
Author Information
Author(s): Grizzi Fabio, Gaetani Paolo, Franceschini Barbara, Di Ieva Antonio, Colombo Piergiuseppe, Ceva-Grimaldi Giorgia, Bollati Angelo, Frezza Eldo E, Cobos E, Baena Riccardo Rodriguez y, Dioguardi Nicola, Chiriva-Internati Maurizio
Primary Institution: Istituto Clinico Humanitas, IRCCS
Hypothesis
Can sperm protein 17 (Sp17) be used as a target for tumor-vaccine strategies in nervous system malignancies?
Conclusion
Sp17 cannot be used as a unique immunotherapeutic target in nervous system cancer due to its heterogeneous expression.
Supporting Evidence
- Sp17 was found in 21% of neuroectodermal tumors and 4% of meningeal tumors.
- None of the peripheral nerve sheath tumors expressed Sp17.
- Immunopositive samples showed heterogeneous expression patterns.
Takeaway
The study looked at a protein called Sp17 in brain tumors and found it in some but not all types, meaning it can't be used alone to treat these cancers.
Methodology
Immunohistochemical analysis of Sp17 expression in surgical specimens from patients with various nervous system tumors.
Potential Biases
Potential bias due to the small sample size and the specific patient population.
Limitations
The study had a limited number of cases and did not assess the correlation of Sp17 expression with clinical outcomes.
Participant Demographics
Mean age of participants was 58 years, with 26 males and 32 females.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website